The Medicine Cabinet Was Always Full: How Network Medicine Reveals Hidden Longevity Drugs in Ordinary Bottles

A new computational method maps existing pharmaceuticals to the hallmarks of aging—and discovers that aspirin may reach more aging pathways than rapamycin.

From a Pile of Genes to a Map of Neighborhoods

For decades, aging research faced a fundamental problem: it looked like a haystack. Scientists had identified over 1,250 genes involved in aging, but these genes seemed scattered and disconnected, with little apparent organization or relationship to one another. How could researchers possibly develop treatments when the target was such a tangled mess?

Network medicine changed everything by reframing the question entirely. Instead of treating aging genes as isolated dots, researchers began mapping them as neighborhoods within the human protein interactome—the vast web of interactions between all our proteins. The breakthrough was connecting these genetic neighborhoods to the eleven established hallmarks of aging: cellular processes like senescence, mitochondrial dysfunction, and stem cell exhaustion. Suddenly, the chaotic pile organized itself into coherent districts, each representing a distinct biological problem.

The hallmarks aren’t isolated islands separated by empty space. Instead, they’re densely interconnected. About 390 genes touch multiple hallmarks simultaneously, acting as biological bridges between different aging processes. The protein TP53, a famous tumor suppressor, is a remarkable example—it spans connections across seven different hallmarks, making it a critical hub in the aging network.

This organizational insight transforms drug development. Instead of searching for a single magic bullet targeting one isolated gene, researchers can now test existing drugs against entire neighborhoods of genes and their interactions. A drug originally developed for cancer, for instance, might influence multiple genes within a hallmark neighborhood, potentially slowing aging pathways through indirect routes scientists hadn’t previously considered. This architectural understanding is what makes drugs repurposed for aging suddenly feasible: the map reveals not just the targets, but the connections between them.

The SHARP Pipeline: Network Proximity and Directionality

The SHARP pipeline (Systematic Hallmark-based Aging Repurposing Pipeline) takes a network-wide approach to identify promising candidates, asking a deceptively simple question: which existing drugs sit close to the genes that drive aging?

The method works in two complementary steps. First, network proximity measures how close a drug’s molecular targets sit to each hallmark’s genetic neighborhood within the interactome—the vast map of protein interactions in human cells. A drug that targets proteins connected to genomic instability genes sits “nearby” in the network, suggesting it might influence that hallmark’s biological processes.

But proximity alone tells an incomplete story. A drug could push aging-related genes in the right direction or the wrong one. The pAGE metric adds crucial directionality, asking whether a drug nudges aging-related genes toward beneficial outcomes or harmful ones. This distinguishes between drugs that combat aging and those that might inadvertently accelerate it.

Applied to 6,442 FDA-approved drugs, SHARP identified 370 candidates proximal to at least one aging hallmark. The results reveal striking differences in drug scope. Aspirin maps to six hallmarks, making it a broad-spectrum candidate. Dasatinib connects to five. Rapamycin—widely celebrated in longevity research—touches only one. This finding suggests that even established longevity drugs may work through narrower channels than previously assumed.

Crucially, SHARP identifies trade-offs: some drug candidates help one hallmark while potentially harming another. This transparency is essential for real-world drug development, where benefits and risks must be weighed against the full biological picture. By combining network proximity with directional analysis, SHARP transforms drug repurposing from speculation into systematic, biology-informed discovery.

The Hidden Pharmacy: Network Drugs and Unexpected Candidates

Roughly one-third of pharmacy shelves may contain hidden longevity treatments—drugs never designed to fight aging, yet possessing unexpected power to do exactly that. Researchers have identified eighty-three “network drugs” that reach critical aging-related cellular modules without directly targeting any known aging gene. These invisible agents escape detection by conventional drug-search methods, which typically scan for direct hits against specific targets.

Consider oxymetazoline, the active ingredient in Afrin nasal decongestant spray. On the surface, it’s a simple topical remedy for congestion. Yet when mapped through network topology—the hidden architecture of cellular communication—it demonstrates measurable connections to fundamental aging hallmarks. Oxymetazoline becomes a case study in unexpected opportunity: a drug sitting openly on pharmacy shelves, potentially harboring benefits overlooked for decades.

This discovery fundamentally reframes our understanding of the medicine cabinet. Rather than viewing it as a collection of single-purpose bottles, we should see it as an interconnected system of secondary opportunities. Medications developed for hypertension, inflammation, or bacterial infections weren’t designed with longevity in mind, yet their molecular fingerprints suggest they might influence aging pathways in ways their original developers never imagined.

The irony is striking: medications developed for unrelated conditions may possess more mechanistic reach into aging than drugs specifically engineered to target it. These eighty-three network drugs represent an enormous, largely unexplored search space. The challenge now lies in clinical validation, transforming computational predictions into evidence-based rejuvenation strategies that could reshape our approach to aging medicine.

Validation Against Reality: The Intervention Testing Program

Theory means nothing without evidence. This network method was rigorously tested against the gold standard of longevity research: the Intervention Testing Program (ITP), a decades-long initiative that has systematically tested compounds in actual mouse lifespan studies.

The results were striking. All eight compounds that successfully extended lifespan in the ITP trials scored positive on the network map, achieving 100% accuracy. Equally important, compounds that failed to extend lifespan showed significantly lower network proximity scores. The method demonstrated genuine discriminative power, distinguishing winners from losers.

The validation extended further. Researchers examined 17 compounds already in human longevity trials, including well-known candidates like metformin and rapamycin. Eleven of these showed significant network proximity to aging hallmarks, suggesting the framework could identify promising candidates for clinical development.

Most convincingly, the team made prospective predictions on ten compounds and then validated these predictions against experimental results published after the method’s predictions were made. This wasn’t hindsight analysis—it was genuine foresight.

This work represents a fundamental shift in drug discovery. Rather than testing thousands of compounds through expensive, time-consuming experiments, researchers can now use network biology to identify the most promising candidates computationally. For longevity research, where traditional drug development timelines stretch across decades, this represents a meaningful shortcut to therapeutics that could extend healthy human lifespan.

The OpenGenes Infrastructure: Building the Foundation

The discovery of potential longevity drugs would not have been possible without decades of foundational work in genomic databases. At the heart of this breakthrough lies OpenGenes, a comprehensive catalog of 2,358 human genes directly associated with aging and longevity. This curated database serves as the primary data layer upon which the entire SHARP pipeline is built, providing researchers with a systematic starting point for analysis.

From this extensive gene catalog, researchers methodically mapped a focused subset of 1,250 genes to specific neighborhoods within the aging network. This structured approach transformed raw genetic data into actionable network architecture, enabling researchers to understand not just individual genes, but how they interact across biological systems.

Complementing this genetic foundation is the protein interactome—a massive repository containing half a million experimentally validated protein interactions. This detailed map of cellular communication provides the topological foundation necessary for calculating proximity and relationships between genes and potential drug targets.

This pre-existing infrastructure represents an invaluable scientific asset. The success of this drug repurposing study underscores a critical principle in modern science: open, comprehensive, and freely accessible databases outperform fragmented, proprietary datasets. By building on shared, transparent genomic resources, researchers can accelerate discovery and democratize access to potentially life-extending treatments.

From Theory to Clinic: ER-100 and the Future of Repurposed Longevity Drugs

The journey from computational prediction to human treatment represents the ultimate test of any scientific theory. Life Biosciences, co-founded by longevity researcher David Sinclair, is now crossing that bridge with ER-100, a compound currently in Phase 1 clinical trials for optic neuropathies. This marks a watershed moment: network-identified drug candidates are moving from mouse models into human subjects, where predictions can be experimentally validated.

What makes ER-100 particularly noteworthy is what it isn’t. This isn’t a novel molecule discovered in a laboratory. Instead, it represents a new clinical indication for an existing drug mechanism—precisely the kind of repurposing that the SHARP pipeline was designed to identify. Rather than waiting years for new compounds to be synthesized and tested, researchers leveraged computational network analysis to find hidden longevity potential in approved therapeutics already in the pharmaceutical arsenal.

This approach sidesteps a traditional bottleneck in drug development. By mapping how existing drugs interact with aging hallmarks through protein networks, the SHARP pipeline identified approximately 370 candidates worthy of investigation. ER-100’s entry into human trials transforms these computational predictions from interesting academic findings into tangible clinical interventions—the gold standard of proof.

Life Biosciences anticipates additional compounds from that candidate list entering human trials by 2026-2027. Each trial will answer a critical question: do the network predictions hold up when tested in actual patients?

This transition from research paper to human testing represents more than bureaucratic progress. It signals the maturation of network medicine as a practical tool for extending human healthspan, not merely as an elegant theoretical framework. The era of drugs repurposed for aging is no longer speculative—it’s clinical reality.